SCHEMBL4054239

SCHEMBL4054239

Cc1ccc(-c2nc3ncc(-c4ccccc4)cc3[nH]2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 1/20 0.52
TP53 P04637 1/20 0.52
HPGD P15428 1/20 0.52
NFKB1 P19838 1/20 0.52
RAB9A P51151 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HSD17B10 Q99714 1/20 0.52
IKBKE Q14164 5/20 0.46
TBK1 Q9UHD2 5/20 0.46
AURKA O14965 5/20 0.45
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
USP30 Q70CQ3 3/20 0.42
CYP3A4 P08684 1/20 0.41
KIT P10721 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052519 0.84 SCD (0.53) KDM4ENPC1ALDH1A1TP53HPGD
SCHEMBL4056702 0.84 AURKA (0.44) KDM4ENPC1ALDH1A1TP53HPGD
SCHEMBL4055186 0.83 KDM4E (0.46) KDM4ENPC1ALDH1A1TP53HPGD
SCHEMBL4057011 0.82 KDM4E (0.44) KDM4ENPC1ALDH1A1TP53HPGD
SCHEMBL4059131 0.81 AURKA (0.56) NPC1RAB9AIKBKETBK1AURKA
SCHEMBL4054236 0.80 SMN1; SMN2 (0.56) KDM4ENPC1ALDH1A1TP53HPGD
SCHEMBL13607894 0.79 NPC1 (0.52) KDM4ENPC1ALDH1A1TP53HPGD
SCHEMBL4050475 0.78 NR1I3 (0.52) KDM4ENPC1ALDH1A1TP53HPGD
SCHEMBL4061906 0.74 MGAM (0.51) AURKACYP3A4KDR
SCHEMBL4058315 0.74 AURKA (0.52) IKBKETBK1AURKANOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B KDM4E 496/4885NPC1 4740/4885ALDH1A1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.